Developer docs
API playgroundTry for free, no card

Search company profiles

Scimega

Full company profile

uuid000ulgj

Namestring
Scimega
Legal namestring
Scimega Research Inc.
Websiteurl
scimega.com
Company typeenum
Private
Founded yearint
1997
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersLaval, Canada
HQ citystring
Laval
HQ countrystring
Canada
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
oncology clinical trials, contract research organization, clinical research services, site feasibility services, regulatory affairs services
Industry2 codes
PRIMARYHLAGAAAL
Specialty Therapeutic-Area CROs (e.g., oncology/rare disease)
SECONDARYHLAGAAAI
Patient Recruitment, Site Feasibility & Trial Enablement CROs
NAICS code4 codes
  • Scientific Research and Development Services5417
  • Research and Development in the Physical, Engineering, and Life Sciences54171
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Other Scientific and Technical Consulting Services541690
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Oncology Clinical Research Services (CRO)
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model1 record
1Oncology Clinical Research Services
TypeProfessional Services
Description

Professional services revenue generated through providing oncology clinical trial management services to biotech and biopharma sponsors. Services include site selection, regulatory strategy, clinical monitoring, and country oversight for Phase 1-3 oncology trials in Canada.

scimega.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure
Pricing details1 tier
1Project-based CRO services for oncology clinical trials
ModelOtherBilling cadenceMulti-year contract
Notes

Pricing is negotiated on a per-project basis based on trial complexity, phase, number of sites, and scope of services. No public pricing available.

scimega.com
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 2 records shown
1Reverse Feasibility Program
Description

A collaborative platform connecting Canadian investigative sites with oncology drug developers, featuring a real-time notification system for Canada-wide enrollment opportunities.

scimega.com
+1 more record
Core offering1 text field

Scimega is a niche Contract Research Organization (CRO) providing oncology clinical trial management services exclusively in Canada for biotech and biopharma sponsors. Its core offering pairs the Reverse Feasibility Program - a collaborative platform connecting sponsors with Canada's top performing investigative sites - with site selection, Health Canada regulatory strategy, provincial ethics navigation, clinical monitoring, and country oversight for Phase 1, 2, and 3 oncology trials. The company has completed 100+ oncology trials and has never been rescued by another CRO.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 9 values shown
  • 50% faster study start-up compared to industry average
+8 more records
Product overview1 text field

Scimega is a niche Canadian oncology CRO founded in 1997 with 29 years of dedicated oncology clinical research experience. The company operates as a single unified service offering centered around the Reverse Feasibility Program, which connects small and mid-sized biopharma companies with a collaborative network of Canada's top performing investigative sites. The core platform is supported by six integrated service modules: Site Selection & Accelerated Study Start-Up, Health Canada Regulatory Strategy, Provincial Ethics Approval Strategy, Clinical Monitoring Services, and Country Oversight. The company specializes exclusively in Phase 1, 2, and 3 oncology clinical trials in Canada, and has never been rescued by another CRO. Scimega delivers 50% faster trial start-up times compared to industry average and maintains 85% source data verification rates.

Product and service8 records
1Reverse Feasibility Program
CategoryCore Oncology CRO Service
Description

Collaborative clinical operations platform that connects a network of Canada's top performing investigative sites with oncology drug developers, providing real-time Canada-wide recruitment notifications and competitive analysis to accelerate oncology trial start-up by 50%.

2Site Selection & Accelerated Study Start-Up
CategoryOncology CRO Service Module
Description

Service module leveraging privileged relationships with site contract managers and legal counsel, using pre-negotiated CTA templates and an extensive library of recent contracts and site budgets to expedite first site open and first patient in timelines.

3Health Canada Regulatory Strategy
CategoryOncology CRO Service Module
Description

Expert regulatory services evaluating CTA dossier completeness, anticipating Health Canada questions to avoid delays, with a 30-day default approval period and parallel CTA review to ethics and contract processes.

4Provincial Ethics Approval Strategy
CategoryOncology CRO Service Module
Description

Navigates centralized provincial research ethics boards (REBs) by leveraging key relationships with centers across Canada to determine optimal provincial or central applicants for faster activation timelines.

5Clinical Monitoring Services
CategoryOncology CRO Service Module
Description

Dedicated oncology-focused CRA team providing site-level support from selection to close-out, featuring consistent CRA site assignment strategy and high-quality data collection with 85% SDV rates.

6Country Oversight
CategoryOncology CRO Service Module
Description

Project management by Clinical Trial Leaders (CTLs) from site selection through study close-out, including regular internal project reviews, CRA oversight, and direct sponsor liaison for Phase I, II and III oncology trials.

7Early Development Phase 1 & 2 Expertise
CategoryOncology CRO Service Module
Description

Specialized expertise in Phase 1 and Phase 2 oncology clinical trials, covering the majority of Scimega's trial portfolio (70% of trials).

8Phase 3 Oncology Clinical Trial Expertise
CategoryOncology CRO Service Module
Description

Specialized expertise in Phase 3 oncology clinical trials, delivered as part of Scimega's exclusive Canada-only oncology CRO offering.

Scale indicator11 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierMinorTypeOthersAnnounced on2023-01-01
Description

Scimega joined BioQuébec in 2023 to support Quebec's biotech and life sciences industry. BioQuébec is an industry association representing Quebec's biotechnology and life sciences companies.

Strategic tierCoreTypeImplementation/ SI/ Consulting PartnerAnnounced on2019-01-01
Description

Scimega officially adopted LEAN methodology as a continuous improvement approach since 2019, working with The Lean Six Sigma Company for professional coaching. The company has a LEAN ambassador who leads improvement projects in collaboration with a professional LEAN coach.

3Society of Quality Assurance (SQA)
Strategic tierMinorTypeOthersAnnounced on2017-01-01
Description

Scimega joined the Society of Quality Assurance in 2017, an organization for QA professionals, demonstrating commitment to quality standards and compliance in clinical research.

scimega.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Network of over 50 Canadian cancer research centers participating in the Reverse Feasibility Program. These sites have privileged relationships with Scimega and routinely share their academic interests and clinical trial needs to ensure placement of pertinent novel cancer clinical trials.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeRegional player
Description

Altasciences is a Canada-headquartered early-phase CRO offering clinical and bioanalytical services from Canadian facilities. Comparable to Scimega as a fellow Canadian-headquartered CRO serving biotech sponsors, though broader in therapeutic scope and focused on early-phase rather than full oncology programs.

TypeDirect peer
Description

Medpace is a mid-sized, therapeutically-focused CRO with particularly strong oncology capabilities and a reputation for operational excellence. Comparable to Scimega in its focused therapeutic model, full-service offerings, and concentration on small/mid-sized biotech sponsors.

TypeBroad incumbent
Description

Fortrea is a global CRO spun out from Labcorp in 2023, offering full-service oncology clinical research. Comparable to Scimega as a broad incumbent in oncology CRO services, though at substantially greater scale and global reach.

TypeDirect peer
Description

Worldwide Clinical Trials is a mid-sized CRO with deep specialization in oncology and other complex therapeutic areas, serving small and mid-sized biopharma. Highly comparable to Scimega in therapeutic focus, customer segment, and emphasis on scientific quality over scale.

TypeDirect peer
Description

Precision for Medicine is a specialty CRO with dedicated oncology and biomarker-driven trial expertise, serving biotech sponsors. Highly comparable to Scimega in oncology specialization, biomarker/precision medicine focus, and small-to-mid biotech customer base.

TypeBroad incumbent
Description

ICON is one of the world's largest CROs with a full-service oncology offering post-PRA Health Sciences merger. Comparable to Scimega as a competitor for oncology trial contracts, though broader in therapeutic scope, scale, and geographic reach.

TypeBroad incumbent
Description

IQVIA is the largest global CRO and clinical technology provider, with extensive oncology capabilities through its IQVIA Biotech and Novella Oncology franchises. Comparable to Scimega as a competitor for oncology trial contracts, particularly for biotech sponsors seeking global reach.

TypeDirect peer
Description

Theradex is an oncology-specialty CRO with a long track record in early-phase oncology trials and a reputation for scientific quality. Closely comparable to Scimega in oncology-only focus, early-phase trial emphasis, and full-service oncology offerings for biotech sponsors.

TypeBroad incumbent
Description

Parexel is a top-5 global CRO with established oncology capabilities, particularly in early-phase and complex trial design. Comparable to Scimega as a broad incumbent competitor targeting small and mid-sized biotech oncology sponsors.

10Veristat
TypeEmerging player
Description

Veristat is a specialized clinical research and biometrics CRO with oncology expertise and a focus on complex, small-to-mid sponsor trials. Comparable to Scimega in therapeutic specialization, customer segment, and emphasis on operational quality for niche oncology programs.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Scimega

Oncology Clinical Research Services (CRO)scimega.com

Scimega firmographics

Firmographics
Name
Scimega
Legal name
Scimega Research Inc.
Website
https://scimega.com
Company type
Private
Founded year
1997
Operating status
Operating
Headcount range
11–50 employees
Ownership category
akta.pro rank

Scimega industry classification

Industry
Product category
Oncology Clinical Research Services (CRO)
NAICS
Scientific Research and Development Services (5417), Research and Development in the Physical, Engineering, and Life Sciences (54171), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Other Scientific and Technical Consulting Services (541690)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGAAAL
Specialty Therapeutic-Area CROs (e.g., oncology/rare disease)
SECONDARYHLAGAAAI
Patient Recruitment, Site Feasibility & Trial Enablement CROs

Keywords

  • Oncology clinical trials
  • Contract research organization
  • Clinical research services
  • Site feasibility services
  • Regulatory affairs services

Where Scimega is headquartered

Location

Headquarters

HQ city
Laval
HQ country
Canada
HQ region
North America

Offices1 record

Markets served

Scimega business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

  1. Oncology Clinical Research Services: Professional services revenue generated through providing oncology clinical trial management services to biotech and biopharma sponsors. Services include site selection, regulatory strategy, clinical monitoring, and country oversight for Phase 1-3 oncology trials in Canada.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractProject-based CRO services for oncology clinical trials

Go-to-market motion3 records

Distribution channels3 records

Marketing channels7 records

Scimega product offering

Product offering

Core offering

Scimega is a niche Contract Research Organization (CRO) providing oncology clinical trial management services exclusively in Canada for biotech and biopharma sponsors. Its core offering pairs the Reverse Feasibility Program - a collaborative platform connecting sponsors with Canada's top performing investigative sites - with site selection, Health Canada regulatory strategy, provincial ethics navigation, clinical monitoring, and country oversight for Phase 1, 2, and 3 oncology trials. The company has completed 100+ oncology trials and has never been rescued by another CRO.

Product overview

Scimega is a niche Canadian oncology CRO founded in 1997 with 29 years of dedicated oncology clinical research experience. The company operates as a single unified service offering centered around the Reverse Feasibility Program, which connects small and mid-sized biopharma companies with a collaborative network of Canada's top performing investigative sites. The core platform is supported by six integrated service modules: Site Selection & Accelerated Study Start-Up, Health Canada Regulatory Strategy, Provincial Ethics Approval Strategy, Clinical Monitoring Services, and Country Oversight. The company specializes exclusively in Phase 1, 2, and 3 oncology clinical trials in Canada, and has never been rescued by another CRO. Scimega delivers 50% faster trial start-up times compared to industry average and maintains 85% source data verification rates.

Differentiator

Problem solved

Functional benefit

Brands

  • Reverse Feasibility Program: A collaborative platform connecting Canadian investigative sites with oncology drug developers, featuring a real-time notification system for Canada-wide enrollment opportunities.
  • Scimega Network Champions Award

Products and services

  • Reverse Feasibility Program Collaborative clinical operations platform that connects a network of Canada's top performing investigative sites with oncology drug developers, providing real-time Canada-wide recruitment notifications and competitive analysis to accelerate oncology trial start-up by 50%.
  • Site Selection & Accelerated Study Start-Up Service module leveraging privileged relationships with site contract managers and legal counsel, using pre-negotiated CTA templates and an extensive library of recent contracts and site budgets to expedite first site open and first patient in timelines.
  • Health Canada Regulatory Strategy Expert regulatory services evaluating CTA dossier completeness, anticipating Health Canada questions to avoid delays, with a 30-day default approval period and parallel CTA review to ethics and contract processes.
  • Provincial Ethics Approval Strategy Navigates centralized provincial research ethics boards (REBs) by leveraging key relationships with centers across Canada to determine optimal provincial or central applicants for faster activation timelines.
  • Clinical Monitoring Services Dedicated oncology-focused CRA team providing site-level support from selection to close-out, featuring consistent CRA site assignment strategy and high-quality data collection with 85% SDV rates.
  • Country Oversight Project management by Clinical Trial Leaders (CTLs) from site selection through study close-out, including regular internal project reviews, CRA oversight, and direct sponsor liaison for Phase I, II and III oncology trials.
  • Early Development Phase 1 & 2 Expertise Specialized expertise in Phase 1 and Phase 2 oncology clinical trials, covering the majority of Scimega's trial portfolio (70% of trials).
  • Phase 3 Oncology Clinical Trial Expertise Specialized expertise in Phase 3 oncology clinical trials, delivered as part of Scimega's exclusive Canada-only oncology CRO offering.

Quantifiable outcome

  • 50% faster study start-up compared to industry average
  • +8 more outcomes

Companies that use Scimega

Customer profile

Named customers2 records

Segments3 records

Ideal customer profiles2 records

Scimega technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Scimega partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered minor and core.

  • BioQuébecminorOthers · 1 January 2023Scimega joined BioQuébec in 2023 to support Quebec's biotech and life sciences industry. BioQuébec is an industry association representing Quebec's biotechnology and life sciences companies.
  • Lean Six SigmacoreImplementation/ SI/ Consulting Partner · 1 January 2019Scimega officially adopted LEAN methodology as a continuous improvement approach since 2019, working with The Lean Six Sigma Company for professional coaching. The company has a LEAN ambassador who leads improvement projects in collaboration with a professional LEAN coach.
  • Society of Quality Assurance (SQA)minorOthers · 1 January 2017Scimega joined the Society of Quality Assurance in 2017, an organization for QA professionals, demonstrating commitment to quality standards and compliance in clinical research.
  • Canadian Cancer Research CenterscoreStrategic or Co-development PartnerNetwork of over 50 Canadian cancer research centers participating in the Reverse Feasibility Program. These sites have privileged relationships with Scimega and routinely share their academic interests and clinical trial needs to ensure placement of pertinent novel cancer clinical trials.

Scale indicators11 records

Recent moves6 records

Expansion highlights5 records

Scimega competitors and assessment

Company assessment

Regional players

  • Altasciences: Altasciences is a Canada-headquartered early-phase CRO offering clinical and bioanalytical services from Canadian facilities. Comparable to Scimega as a fellow Canadian-headquartered CRO serving biotech sponsors, though broader in therapeutic scope and focused on early-phase rather than full oncology programs.

Direct peers

  • Medpace: Medpace is a mid-sized, therapeutically-focused CRO with particularly strong oncology capabilities and a reputation for operational excellence. Comparable to Scimega in its focused therapeutic model, full-service offerings, and concentration on small/mid-sized biotech sponsors.
  • Worldwide Clinical Trials: Worldwide Clinical Trials is a mid-sized CRO with deep specialization in oncology and other complex therapeutic areas, serving small and mid-sized biopharma. Highly comparable to Scimega in therapeutic focus, customer segment, and emphasis on scientific quality over scale.
  • Precision for Medicine: Precision for Medicine is a specialty CRO with dedicated oncology and biomarker-driven trial expertise, serving biotech sponsors. Highly comparable to Scimega in oncology specialization, biomarker/precision medicine focus, and small-to-mid biotech customer base.
  • Theradex: Theradex is an oncology-specialty CRO with a long track record in early-phase oncology trials and a reputation for scientific quality. Closely comparable to Scimega in oncology-only focus, early-phase trial emphasis, and full-service oncology offerings for biotech sponsors.

Broad incumbents

  • Fortrea (formerly Labcorp Drug Development): Fortrea is a global CRO spun out from Labcorp in 2023, offering full-service oncology clinical research. Comparable to Scimega as a broad incumbent in oncology CRO services, though at substantially greater scale and global reach.
  • ICON plc: ICON is one of the world's largest CROs with a full-service oncology offering post-PRA Health Sciences merger. Comparable to Scimega as a competitor for oncology trial contracts, though broader in therapeutic scope, scale, and geographic reach.
  • IQVIA: IQVIA is the largest global CRO and clinical technology provider, with extensive oncology capabilities through its IQVIA Biotech and Novella Oncology franchises. Comparable to Scimega as a competitor for oncology trial contracts, particularly for biotech sponsors seeking global reach.
  • Parexel: Parexel is a top-5 global CRO with established oncology capabilities, particularly in early-phase and complex trial design. Comparable to Scimega as a broad incumbent competitor targeting small and mid-sized biotech oncology sponsors.

Emerging players

  • Veristat: Veristat is a specialized clinical research and biometrics CRO with oncology expertise and a focus on complex, small-to-mid sponsor trials. Comparable to Scimega in therapeutic specialization, customer segment, and emphasis on operational quality for niche oncology programs.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks7 records

Key highlights7 records

Customer concentration

Scimega social profiles

Digital presence

Scimega financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Scimega leadership team

Management profile

Number of profiles

Profiles4 records

Scimega funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Scimega M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Scimega

What does Scimega do?

Scimega is a niche Contract Research Organization (CRO) providing oncology clinical trial management services exclusively in Canada for biotech and biopharma sponsors. Its core offering pairs the Reverse Feasibility Program - a collaborative platform connecting sponsors with Canada's top performing investigative sites - with site selection, Health Canada regulatory strategy, provincial ethics navigation, clinical monitoring, and country oversight for Phase 1, 2, and 3 oncology trials. The company has completed 100+ oncology trials and has never been rescued by another CRO.

Is Scimega a public or private company?

Scimega is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Scimega founded?

Scimega was founded in 1997. It employs 11 to 50 people.

Where is Scimega based?

Scimega is headquartered in Laval, Canada, in the North America region.

How does Scimega make money?

One revenue line is on record: oncology Clinical Research Services.

Who are Scimega's main competitors?

Altasciences is listed as a regional player. Direct peers are Medpace, Worldwide Clinical Trials, Precision for Medicine and Theradex. Broad incumbents are Fortrea (formerly Labcorp Drug Development), ICON plc, IQVIA and Parexel. Veristat is listed as an emerging player.

Does Scimega have an API?

No public API is recorded for Scimega.

What industry is Scimega in?

Scimega's product category is Oncology Clinical Research Services (CRO). Its primary akta.pro industry code is HLAGAAAL, Specialty Therapeutic-Area CROs (e.g., oncology/rare disease), with a secondary code of HLAGAAAI, Patient Recruitment, Site Feasibility & Trial Enablement CROs. Its NAICS code is 5417 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals